Proteus Digital Health Files for IPO: Pioneering Smart Pills to Transform Chronic Disease Management

In the United States, one-quarter of the population suffers from one or two chronic conditions, such as hypertension or type 2 diabetes. Three-quarters of healthcare expenditures are spent on the treatment of patients with chronic diseases. No matter how tirelessly scientists at pharmaceutical giants labor to develop new drugs, their efforts are futile if patients fail to adhere to prescribed regimens, as non-adherence inevitably compromises therapeutic efficacy. However, managing daily medication intake is far from simple.

50% of prescription medications are taken without medical supervision, which may lead to incomplete therapeutic efficacy or treatment failure, ultimately resulting in recurrent treatments and causing waste of medical resources and increased costs. Therefore, it is essential to adopt appropriate information technologies and establish new approaches to disease management, thereby building a more effective healthcare system for patients.


In theory, people should never ingest computer chips—it sounds uncomfortable and unpleasant, and they certainly don’t taste as good as dessert. Yet Proteus Digital Health has worked its magic, conjuring up ingestible electronic pills as if by sleight of hand.

Proteus, founded in 2001 and headquartered in Redwood City, California, is dedicated to developing digital health products that collect various human metrics—including behavioral, physiological, and treatment-related data such as medication adherence, heart rate, sleep patterns, physical activity, and stress levels—providing consumers with personalized health management tools.

Simply put, the digestible microchip developed by Proteus works like this: once you swallow it, the chip activates inside your body and transmits all critical medical data directly to your smartphone. Of course, this chip does not alter your internal organs or turn you into a cyborg.



How Exactly Does Proteus Work?

The company’s technology sounds like science fiction. At the core of Proteus is a pill called Helius, which integrates an ingestible sensor no larger than a grain of sand to monitor how medications are metabolized and take effect in the body. After the patient swallows the pill, it reaches the stomach, where electrodes within the sensor draw power from gastric acid. Working in conjunction with a skin-worn patch, the sensor measures various physiological parameters—such as heart rate, respiration, body angle, activity levels, and sleep patterns—to provide insights into the user’s health status. The sensor also transmits this data to a smartphone.

Although the product named Helius is well-suited for self-care applications, its primary users are not patients themselves but rather those who provide care. For chronic disease patients requiring long-term care, informal family caregivers, rather than medical professionals, constitute the main source of support, with their numbers being ten times greater than that of healthcare professionals. Consequently, patient family members, physicians, and even insurance companies can access data captured by the Proteus system. Of course, patients retain the right to choose whether to share this data or deny others access to it.

Product Features:

Facilitating Condition Monitoring: Understanding patients' health habits helps patients, their families, and healthcare professionals stay informed about the patients' physical condition at any time.

More Personalized Care Plans: Proteus Analytics Service Reports Enable Physicians to Better Tailor Patient Solutions.

Establishing Efficient Targeted Therapy: The Proteus Analytics Service Report includes daily health habits and medication adherence patterns, enabling physicians to quickly identify information on medications and treatments.

The Development History of Proteus:


Proteus has been hailed by the industry as one of the mobile health companies most likely to go public in 2015. Currently, Proteus is collaborating with numerous prominent companies and research institutions, including its digital medicine partners Otsuka Pharmaceutical and Novartis; its consumer and medical wearable sensor product partners Vancive (a subsidiary of Avery Dennison) and BodyMedia; as well as Oracle, the Eastern Academic Health Science Network (EAHSN), the Northern Health Science Alliance (NHSA), the University of Oxford, Oxford University Hospitals NHS Foundation Trust, and the Oxford Academic Health Science Network (OAHSN).

Prior to Helius, the company was dedicated to developing a clinical-stage technology platform. As a platform-based enterprise, it leveraged novel smart pharmaceuticals to provide personalized visualization, management of drug intake, and monitoring of physiological responses to medications. The company’s first product was a novel pacing device equipped with sensing technology to enable cardiac resynchronization therapy. In collaboration with world-leading manufacturers of cardiovascular implantable devices, the product entered clinical studies in 2008.

On August 13, 2010, the company obtained CE marking certification in the European Union, allowing it to market its ingestible sensors and personal physiological monitoring systems. It also received ISO 13485:2003 design certification, marking a significant milestone for the company. Proteus’s ingestible sensor and personal physiological monitoring system, known as the Raisin System, records physiological data—such as heart rate, activity, body angle, and patient-recorded information—upon ingestion of the sensor at discrete time points (e.g., during specific medication intake). Unique ingestion events and personalized physiological data are transmitted via Bluetooth to computerized devices, such as smartphones with mobile health applications. The sensor is attached to the patient’s skin using an adhesive and worn like a bandage.

As part of the Proteus integrated medication system, the development of the Raisin system will link to sensor-equipped medications, enabling direct personalization of users’ physiological responses and treatment regimens. Proteus and its partners have begun developing systems that integrate these products for the treatment of diabetes, cardiovascular diseases, mental disorders, and infectious diseases.

On June 7, 2011, Proteus and Avery Dennison Medical Solutions jointly developed a patch-based wearable sensor device. Proteus provided the solution, while Avery Dennison was responsible for the development and manufacturing of adhesive material technologies for the mass production of this wearable sensor device.

On July 14, 2011, the U.S. Patent and Trademark Office granted Raisin System Patent No. 7,978,064. Its unique component is the Ingestion Event Marker (IEM), a microelectromechanical device made of a material found in the grain chain, resembling a tiny grain of sand. The IEM can be integrated into any medication tablet or capsule to monitor ingestion in real time, thereby helping to measure and improve patient adherence to medication and dosing regimens.

On December 15, 2011, with Brinsmead joining Proteus as European Chairman, Helius was subsequently launched. This product is based on the Raisin system. Helius provides effective solutions for patients currently facing medical and health issues. By integrating sensor-enabled tablets, wearable physiological monitors, advanced mobile health user experiences, and information services, the launch of Helius enables consumers to remain safely at home while being remotely cared for by their loved ones. Initially launched in the UK in 2012, Helius was sold through pharmacy chains, supported by community physicians, and paid for by consumers and their families. The product is also utilized in home care services, nursing homes, and other institutions to enhance quality of care and medical efficiency.

In 2012, two major products were launched: Metria, a remote body monitoring system developed in partnership with Avery Dennison, and Helius, introduced in collaboration with Lloydspharmacy. These two products signify the emergence of a new industry in health tech, where sensor-enabled devices are linked to the human body to enable continuous monitoring and deliver personalized services.

On July 5, 2012, Proteus and Otsuka Pharmaceutical Co., Ltd. entered into a global exclusive licensing and collaboration agreement to develop and commercialize a new class of medicines. This new medication will be based on Otsuka Pharmaceutical’s products and Proteus’s digital health feedback system, incorporating Proteus’s novel sensing technology.

On July 30, 2012, the FDA approved ingestible sensors as medical devices. Proteus had been applying for this innovation since 2008, marking a new category in medical instruments and patient care.
FDA approval marks a new milestone in digital health. For the first time, it demonstrates that the integration of directly digitized medications with wireless devices may become the new standard for improving medication adherence and effectively supporting disease management.

On May 1, 2013, Proteus and Oracle announced a partnership. Proteus’s ingestible sensors may be integrated with Oracle’s clinical trial products—such as Oracle Health Sciences InForm, Oracle Life Sciences Database, and Oracle’s Siebel Clinical Trial Management System—via the secure, reliable, and scalable Oracle Health Sciences Cloud Platform.

During its development, the company has engaged in early discussions with insurance providers regarding reimbursement issues, with the primary obstacle being the innovative nature of the technology. Currently, healthcare payment systems remain focused on treatment rather than monitoring patients’ health status. Proteus now needs to persuade European and U.S. healthcare payers to adopt Helius and provide coverage for it.

The company is negotiating agreements with national health insurance authorities, such as the UK’s National Health Service (NHS), to establish digital healthcare platforms. Proteus currently holds more than 500 patents and patent applications related to digital health technologies and their applications. Prior to obtaining FDA clearance and EU CE marking, Proteus actively filed for various patents to secure a dominant position in the patent landscape. The author believes that this strategy has been an indispensable factor enabling Proteus to gradually emerge as a leader in the field of digital therapeutics.

Digital medicine is a brand-new concept, but every technology was once new. To promote this technology, Proteus must prove that the device can help patients while reducing costs.

Proteus: Funding Status and Future Prospects:

On May 1, 2001, the company secured an undisclosed amount in Series A financing. On December 19, 2003, it raised $1 million in Series B financing from Asset Management Ventures (AMV). On January 1, 2006, it again received $1.3 million in Series C financing from AMV. On July 10, 2008, it obtained $350,000 in Series D financing from AMV. On December 31, 2009, and May 16, 2012, it secured venture capital investments of $25.4 million and $17.5 million, respectively. On May 1, 2013, it raised $62.5 million in Series F financing from AMV, Oracle, and Novartis. On January 21, 2014, it obtained $31.6 million in debt financing from Silicon Valley Bank and Oxford Finance Corporation. On June 2, 2014, it closed a $172 million Series G financing round.

Over the past decade, Proteus has secured more than $300 million in total investment. Its co-founder and CEO is Andrew Thompson, whose personal prestige and track record of past successes have been among the key factors attracting investor funding. He serves on the selection committee for the World Economic Forum’s Technology Pioneers program and is also a co-founder of Summit School. He holds master’s degrees in engineering from the University of Cambridge, education from Stanford University, and business from Stanford Graduate School of Business. Thompson was one of the founders of FemRx, which went public on NASDAQ in 1996 and was subsequently acquired by Johnson & Johnson. Another company he founded, CardioRhythm, was acquired by Medtronic in 1992.


Many analysts predict that Proteus will ultimately be acquired, partly because its investor roster includes pharmaceutical and medical device companies such as Medtronic, Novartis, and St. Jude Medical. Thompson has stated that while these companies have clearly expressed interest in Proteus’s technology, it remains unclear whether this interest extends to an intention to acquire the company.

(Editor: Zhang Nan)

To learn more about VCBeat’s series “30 Most Promising Healthcare Startups to Watch in 2015,” please click the link “Series Report: Master Index”